1 min read
J&J Says Phase 4 Data Showed Tremfya Reduced Pain and Stiffness
The findings involved patients with psoriatic arthritis and axial involvement, with reductions reported at week 24.

Johnson & Johnson said Phase 4 data showed Tremfya led to reductions in pain, stiffness, swelling and fatigue among patients with psoriatic arthritis and axial involvement, with findings reported at week 24.
Tremfya, also known as guselkumab, is an interleukin-23 antagonist.